Modification of Immunological Parameters, Oxidative Stress Markers, Mood Symptoms, and Well-Being Status in CFS Patients after Probiotic Intake: Observations from a Pilot Study. — CFSMEATLAS
Modification of Immunological Parameters, Oxidative Stress Markers, Mood Symptoms, and Well-Being Status in CFS Patients after Probiotic Intake: Observations from a Pilot Study.
Venturini, Letizia, Bacchi, Sara, Capelli, Enrica et al. · Oxidative medicine and cellular longevity · 2019 · DOI
Quick Summary
This study tested whether taking a specific combination of probiotic supplements (beneficial bacteria) could help people with ME/CFS. Researchers measured changes in immune function, inflammation markers, oxidative stress, and mood before and after patients took probiotics. The results showed improvements in well-being and reductions in inflammatory markers, though one patient experienced a temporary worsening of fatigue symptoms.
Why It Matters
Dysbiosis and intestinal barrier dysfunction have emerged as potential contributors to ME/CFS pathophysiology. This study provides preliminary evidence that targeted microbial interventions may modulate immune and oxidative parameters in ME/CFS, opening a new therapeutic avenue. However, the mechanism linking symptom severity to immune activation (illustrated by the one patient flare) warrants careful investigation before clinical adoption.
Observed Findings
Inflammatory parameters (cytokines, fecal calprotectin, ESR, immunoglobulins) were reduced after probiotic intake in the study population.
Well-being status improved following probiotic administration.
One patient experienced a reactivation of fatigue symptoms despite reduction in inflammatory markers.
No serious adverse effects were observed in the cohort.
The patient with symptom exacerbation had a clinical history of CFS/ME onset following mononucleosis infection.
Inferred Conclusions
Probiotics may modify inflammatory and oxidative dysfunction parameters in ME/CFS patients.
Certain probiotic combinations appear safe for most ME/CFS patients based on this preliminary observation.
Abnormal immune system stimulation in response to probiotics may occur in patients with specific viral disease histories, potentially triggering symptom flares.
Gut dysbiosis and associated intestinal barrier dysfunction may be a targetable mechanism in ME/CFS pathophysiology.
Remaining Questions
What are the optimal probiotic strains and dosing regimens for ME/CFS, and do they differ based on patient phenotype or disease history?
What This Study Does Not Prove
This pilot study does not establish that probiotics are a clinically effective treatment for ME/CFS in the general population—it lacks a placebo control group and blinding, making placebo response and bias possible. The observation of symptom worsening in one patient suggests potential risks and highlights that immune stimulation may not benefit all patients, particularly those with specific clinical histories. Correlation between reduced inflammatory markers and symptom improvement does not prove causation.
Why did immune activation exacerbate fatigue in one patient while improving outcomes in others—what baseline immune or viral markers predict this differential response?
Does symptom improvement correlate with specific changes in the microbiota composition, barrier function, or particular cytokine profiles?
What is the durability of any clinical benefit, and is long-term probiotic administration safe and effective in ME/CFS?